Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer

ReachMD Healthcare Image
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Alterations in ERBB2, the gene encoding HER2, have been recognized as drivers in the development of NSCLC. Therefore, HER2 is an actionable biomarker that has emerged in NSCLC diagnosis and treatment. HER2 mutations activate the HER2 signaling pathway, which facilitates oncogenic transformation and increases tumor proliferation. Although practice guidelines recommend molecular testing to identify alterations, the interpretation of tests and application of testing results to treatment decisions remain areas of educational need. Despite HER2 testing and targeted therapies changing the treatment practices for other solid tumors, the previous standard of care for NSCLC has resulted in persistently low 5-year survival rates in contrast to the high rates of survival for breast cancer. However, successful targeting of HER2-activating mutations in advanced NSCLC has now been achieved through the use of antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd). By effectively targeting HER2-activating mutations, ADCs have emerged as a promising treatment approach for advanced NSCLC. 

    In this educational activity, the expert faculty Chairperson will summarize relevant and timely information on NSCLC with HER2-mutant or overexpressing alterations and highlight the use of HER2-directed ADCs in NSCLC. The Chairperson will also provide their perspectives on the top key takeaways and why they are important for clinical practice consideration.

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty, Joshua E. Reuss, MD, reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: Advisory board/consulting; Sanofi/Genzyme, Personalis, Guardant Health, Inc., AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, Arcus, AbbVie, Daiichi-Sankyo, Inc., Catalym, Seagen, Gilead, Janssen Oncology, Novocure, Regeneron. Advisory board/consulting honoraria; AstraZeneca Pharmaceuticals, Merck & Co. Research/Grants; Genentech/Roche, Verastem Inc., Nuvalent, LUNGevity Foundation, Exelixis, Inc. (all to institution).

    The directors, planners, managers, peer reviewers, and relevant staff reported the  following financial relationships they have with any ineligible  company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman,  PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C ; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply guideline recommendations for patients with NSCLC to detect and identify HER2 alterations to optimize patient outcomes
    • Develop evidence-based approaches to incorporating HER2-directed therapies (eg, ADCs) into the treatment sequence for NSCLC when appropriate
    • Outline team-based strategies to anticipate, mitigate, and manage potential treatment-related AEs in patients with NSCLC receiving HER2-directed treatment
  • Target Audience

    This educational activity is designed for community medical oncologists, pathologists/lab professionals, pulmonologists, thoracic surgical oncologists, oncology nurses, nurse practitioners, physician assistants, clinical pharmacists, respiratory therapists, and other healthcare professionals who are part of the interprofessional team responsible for the treatment and therapeutic management of patients with NSCLC.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for 0.5 AMA PRA Category 1 Credit(s)™.

    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits.  Approval is valid until 7/19/25. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education JA4008106-0000-24-037-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours. Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.5 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo.

  • Disclaimer

    Disclosure of Unlabeled Use                                          
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

    Disclaimer     
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed orsuggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    There is no fee for this educational activity.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying AXISMedEd…
but how about a more personalized experience?

Register for free